LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Начало・Списък с акции・Schrodinger Inc

Schrodinger Inc

Затворен

СекторЗдравеопазване

12.6 -1.25

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.28

Максимум

13.15

Ключови измерители
By Trading Economics
Приходи	-196M -60M
Продажби	-29M 59M
EPS	-0.621
Марж на печалбата	-102.456
Служители	850
EBITDA	-85M -49M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+51.69% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-13M 950M
Предишно отваряне	13.85
Предишно затваряне	12.6

Настроения в новините

By Acuity

50%

162 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

23.27 / 26.13 Подкрепа & съпротива

Schrodinger Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2026 г., 22:54 ч. UTC

Печалби

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.05.2026 г., 23:17 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13.05.2026 г., 23:16 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13.05.2026 г., 23:15 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13.05.2026 г., 23:14 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Печалби

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13.05.2026 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13.05.2026 г., 22:24 ч. UTC

Печалби

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Organic Revenue Growth 25%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Revenue Growth 47%>XRO.AU

13.05.2026 г., 22:22 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13.05.2026 г., 22:18 ч. UTC

Печалби

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13.05.2026 г., 22:16 ч. UTC

Печалби

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13.05.2026 г., 22:13 ч. UTC

Печалби

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13.05.2026 г., 22:12 ч. UTC

Печалби

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero Did Not Declare a Dividend>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13.05.2026 г., 22:09 ч. UTC

Печалби

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13.05.2026 г., 22:00 ч. UTC

Печалби

Cisco to Shed Jobs for All-In AI Push -- Update

13.05.2026 г., 21:11 ч. UTC

Печалби

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Schrodinger Inc Прогноза

Ценова цел

By TipRanks

51.69% нагоре

12-месечна прогноза

Среден 19.25 USD 51.69%

Висок 24 USD

Нисък 13 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Schrodinger Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Schrodinger Inc през последните 3 месеца.

Техническа оценка

By Trading Central

23.27 / 26.13Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

162 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.